Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques. This study will assess how safe and effective cedirogant (ABBV-157) is compared to placebo in adult participants with moderate to severe psoriasis. Efficacy and safety-related measurements are assessing disease activity in participants with plaque psoriasis. Cedirogant (ABBV-157) is an investigational drug being developed for the treatment of chronic plaque psoriasis. Participants will be put into 1 of 4 groups, called treatment arms and each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Approximately 200 adult participants with moderate to severe plaque psoriasis will be enrolled at approximately 45 sites. Participants will receive oral daily doses of cedirogant or placebo capsules for 16 weeks. There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.
From 18 Years to 65 Years.
- Participants with stable moderate to severe plaque psoriasis of at least 6 months
duration and who are candidates for systemic therapy or phototherapy.
- Primary non-responders to previous anti-IL-17 (e.g., secukinumab, ixekizumab,
brodalumab), anti-IL-23 (e.g., guselkumab, tildrakizumab, risankizumab), or
anti-IL-12/23 (e.g., ustekinumab) treatment for chronic plaque psoriasis.
- Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis,
medication-induced or medication exacerbated psoriasis, or new onset guttate psoriasis
or any other skin disease which may interfere with assessment of chronic plaque